If in 2026 and 2027 we collect information that shows that GLP-1 agonist semaglutides are being abused in sport, they could be banned before the Los Angeles Olympics, Professor Rabin revealed, confirming WADA will continue to monitor for possible misuse of semaglutide in-competition and out-of-competition in 2026 along with other drugs such as tirzepatide, another diabetes medication
This profile makes BPC-157 more difficult to interpret than peptides whose experimental readouts are directly linked to receptor occupancy or a defined receptor-to-pathway cascade
Considering the potential for therapeutic development of (in)GSH, the established safety and tolerability data, biological plausibility, and pilot level clinical evidence of benefit are further supported with this demonstration that (in)GSH is able to augment brain GSH levels
Holst, J
Avoiding Pitfalls When Taking GLP-1 Agonists Such as Semaglutide The latest buzz in the medical world is the use of GLP-1 agonists, specifically for weight loss
Headaches or difficulty concentrating